Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eviplera for HIV NPEP in MSM
NCT01715636Phase 4Completed
- Start
- Dec 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + rilpivirine + tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV). Primary endpoint: Safety of 28 days of NPEP. Started Dec 2012; status: completed.
02
Drugs
emtricitabine + rilpivirine + tenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01715636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01715636.